Advancing Trypanosoma cruzi N-myristoyltransferase as a drug target for Chagas disease through in silico discovery and biochemical evaluation

Autores
González García, Diana; Torres, Angel; Talevi, Alan; Alberca, Lucas Nicolás; Beltran, Miguel A.; Lara, Frida; Da Silva Ferreira, Marina; Farani, Priscila S. G.; Almeida, Igor C.; Maldonado, Rosa A.
Año de publicación
2026
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: N-myristoylation is a crucial lipid modification that governs protein localization, intracellular trafficking, and function in eukaryotic cells. The enzyme N-myristoyltransferase (NMT), which catalyzes this modification, has emerged as an attractive drug target for parasitic diseases. In this study, we performed a comprehensive biochemical and antiparasitic evaluation of Trypanosoma cruzi NMT (TcNMT), utilizing novel "in silico–identified inhibitors” to assess its potential as a therapeutic agent for Chagas disease.Methods: Recombinant TcNMT was cloned, expressed, and purified for enzymatic characterization. Catalytic activity and substrate affinity were evaluated using a fluorescence-based assay. Four in-silico-selected NMT inhibitors were screened for (i) enzyme inhibition, (ii) cytotoxicity in human cardiomyocytes, and (iii) antiparasitic activity in T. cruzi–infected cardiomyocytes. QUINE and the reference inhibitor DDD85646 were further characterized by calculating selectivity indices. Proteomic profiling of myristoylated proteins was conducted in amastigotes and trypomastigotes following treatment with DDD85646 to identify pathway-level effects.Results: All recombinant TcNMT preparations were catalytically active and displayed high affinity for peptide substrates. Among the screened compounds, QUINE showed moderate antiparasitic efficacy but very low cytotoxicity, yielding a high selectivity index (SI = 28.11). In contrast, DDD85646 exhibited greater antiparasitic potency but substantially higher host-cell toxicity (SI = 4.67). Proteomic analysis of DDD85646-treated parasites revealed downregulation of myristoylated proteins in both life stages, including ARF GTPases and enzymes associated with vesicular trafficking and lipid metabolism. Host cell proteomes remained largely unchanged.Discussion: Biochemical characterization and phenotypic testing support TcNMT as a viable therapeutic target for Chagas disease. QUINE demonstrates the most favorable pharmacological profile, combining antiparasitic activity with excellent selectivity and low host toxicity, making it a strong lead candidate for future drug optimization. Proteomics data indicate that NMT inhibition disrupts critical pathways required for parasite viability yet spares host cellular machinery, reinforcing the mechanistic selectivity of TcNMT targeting. Further studies are warranted to improve potency and evaluate in vivo efficacy.
Laboratorio de Investigación y Desarrollo de Bioactivos
Materia
Biología
Chagas disease
Trypanosoma cruzi
Inhibition
N-myristoyl-transferase
Drug targets
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/195367

id SEDICI_51eb0483a5f09ad57240fcf84bf5894b
oai_identifier_str oai:sedici.unlp.edu.ar:10915/195367
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Advancing Trypanosoma cruzi N-myristoyltransferase as a drug target for Chagas disease through in silico discovery and biochemical evaluationGonzález García, DianaTorres, AngelTalevi, AlanAlberca, Lucas NicolásBeltran, Miguel A.Lara, FridaDa Silva Ferreira, MarinaFarani, Priscila S. G.Almeida, Igor C.Maldonado, Rosa A.BiologíaChagas diseaseTrypanosoma cruziInhibitionN-myristoyl-transferaseDrug targetsIntroduction: N-myristoylation is a crucial lipid modification that governs protein localization, intracellular trafficking, and function in eukaryotic cells. The enzyme N-myristoyltransferase (NMT), which catalyzes this modification, has emerged as an attractive drug target for parasitic diseases. In this study, we performed a comprehensive biochemical and antiparasitic evaluation of Trypanosoma cruzi NMT (TcNMT), utilizing novel "in silico–identified inhibitors” to assess its potential as a therapeutic agent for Chagas disease.Methods: Recombinant TcNMT was cloned, expressed, and purified for enzymatic characterization. Catalytic activity and substrate affinity were evaluated using a fluorescence-based assay. Four in-silico-selected NMT inhibitors were screened for (i) enzyme inhibition, (ii) cytotoxicity in human cardiomyocytes, and (iii) antiparasitic activity in T. cruzi–infected cardiomyocytes. QUINE and the reference inhibitor DDD85646 were further characterized by calculating selectivity indices. Proteomic profiling of myristoylated proteins was conducted in amastigotes and trypomastigotes following treatment with DDD85646 to identify pathway-level effects.Results: All recombinant TcNMT preparations were catalytically active and displayed high affinity for peptide substrates. Among the screened compounds, QUINE showed moderate antiparasitic efficacy but very low cytotoxicity, yielding a high selectivity index (SI = 28.11). In contrast, DDD85646 exhibited greater antiparasitic potency but substantially higher host-cell toxicity (SI = 4.67). Proteomic analysis of DDD85646-treated parasites revealed downregulation of myristoylated proteins in both life stages, including ARF GTPases and enzymes associated with vesicular trafficking and lipid metabolism. Host cell proteomes remained largely unchanged.Discussion: Biochemical characterization and phenotypic testing support TcNMT as a viable therapeutic target for Chagas disease. QUINE demonstrates the most favorable pharmacological profile, combining antiparasitic activity with excellent selectivity and low host toxicity, making it a strong lead candidate for future drug optimization. Proteomics data indicate that NMT inhibition disrupts critical pathways required for parasite viability yet spares host cellular machinery, reinforcing the mechanistic selectivity of TcNMT targeting. Further studies are warranted to improve potency and evaluate in vivo efficacy.Laboratorio de Investigación y Desarrollo de Bioactivos2026-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/195367enginfo:eu-repo/semantics/altIdentifier/issn/2296-889Xinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fmolb.2025.1666768info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2026-06-23T11:17:02Zoai:sedici.unlp.edu.ar:10915/195367Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292026-06-23 11:17:02.677SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Advancing Trypanosoma cruzi N-myristoyltransferase as a drug target for Chagas disease through in silico discovery and biochemical evaluation
title Advancing Trypanosoma cruzi N-myristoyltransferase as a drug target for Chagas disease through in silico discovery and biochemical evaluation
spellingShingle Advancing Trypanosoma cruzi N-myristoyltransferase as a drug target for Chagas disease through in silico discovery and biochemical evaluation
González García, Diana
Biología
Chagas disease
Trypanosoma cruzi
Inhibition
N-myristoyl-transferase
Drug targets
title_short Advancing Trypanosoma cruzi N-myristoyltransferase as a drug target for Chagas disease through in silico discovery and biochemical evaluation
title_full Advancing Trypanosoma cruzi N-myristoyltransferase as a drug target for Chagas disease through in silico discovery and biochemical evaluation
title_fullStr Advancing Trypanosoma cruzi N-myristoyltransferase as a drug target for Chagas disease through in silico discovery and biochemical evaluation
title_full_unstemmed Advancing Trypanosoma cruzi N-myristoyltransferase as a drug target for Chagas disease through in silico discovery and biochemical evaluation
title_sort Advancing Trypanosoma cruzi N-myristoyltransferase as a drug target for Chagas disease through in silico discovery and biochemical evaluation
dc.creator.none.fl_str_mv González García, Diana
Torres, Angel
Talevi, Alan
Alberca, Lucas Nicolás
Beltran, Miguel A.
Lara, Frida
Da Silva Ferreira, Marina
Farani, Priscila S. G.
Almeida, Igor C.
Maldonado, Rosa A.
author González García, Diana
author_facet González García, Diana
Torres, Angel
Talevi, Alan
Alberca, Lucas Nicolás
Beltran, Miguel A.
Lara, Frida
Da Silva Ferreira, Marina
Farani, Priscila S. G.
Almeida, Igor C.
Maldonado, Rosa A.
author_role author
author2 Torres, Angel
Talevi, Alan
Alberca, Lucas Nicolás
Beltran, Miguel A.
Lara, Frida
Da Silva Ferreira, Marina
Farani, Priscila S. G.
Almeida, Igor C.
Maldonado, Rosa A.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Biología
Chagas disease
Trypanosoma cruzi
Inhibition
N-myristoyl-transferase
Drug targets
topic Biología
Chagas disease
Trypanosoma cruzi
Inhibition
N-myristoyl-transferase
Drug targets
dc.description.none.fl_txt_mv Introduction: N-myristoylation is a crucial lipid modification that governs protein localization, intracellular trafficking, and function in eukaryotic cells. The enzyme N-myristoyltransferase (NMT), which catalyzes this modification, has emerged as an attractive drug target for parasitic diseases. In this study, we performed a comprehensive biochemical and antiparasitic evaluation of Trypanosoma cruzi NMT (TcNMT), utilizing novel "in silico–identified inhibitors” to assess its potential as a therapeutic agent for Chagas disease.Methods: Recombinant TcNMT was cloned, expressed, and purified for enzymatic characterization. Catalytic activity and substrate affinity were evaluated using a fluorescence-based assay. Four in-silico-selected NMT inhibitors were screened for (i) enzyme inhibition, (ii) cytotoxicity in human cardiomyocytes, and (iii) antiparasitic activity in T. cruzi–infected cardiomyocytes. QUINE and the reference inhibitor DDD85646 were further characterized by calculating selectivity indices. Proteomic profiling of myristoylated proteins was conducted in amastigotes and trypomastigotes following treatment with DDD85646 to identify pathway-level effects.Results: All recombinant TcNMT preparations were catalytically active and displayed high affinity for peptide substrates. Among the screened compounds, QUINE showed moderate antiparasitic efficacy but very low cytotoxicity, yielding a high selectivity index (SI = 28.11). In contrast, DDD85646 exhibited greater antiparasitic potency but substantially higher host-cell toxicity (SI = 4.67). Proteomic analysis of DDD85646-treated parasites revealed downregulation of myristoylated proteins in both life stages, including ARF GTPases and enzymes associated with vesicular trafficking and lipid metabolism. Host cell proteomes remained largely unchanged.Discussion: Biochemical characterization and phenotypic testing support TcNMT as a viable therapeutic target for Chagas disease. QUINE demonstrates the most favorable pharmacological profile, combining antiparasitic activity with excellent selectivity and low host toxicity, making it a strong lead candidate for future drug optimization. Proteomics data indicate that NMT inhibition disrupts critical pathways required for parasite viability yet spares host cellular machinery, reinforcing the mechanistic selectivity of TcNMT targeting. Further studies are warranted to improve potency and evaluate in vivo efficacy.
Laboratorio de Investigación y Desarrollo de Bioactivos
description Introduction: N-myristoylation is a crucial lipid modification that governs protein localization, intracellular trafficking, and function in eukaryotic cells. The enzyme N-myristoyltransferase (NMT), which catalyzes this modification, has emerged as an attractive drug target for parasitic diseases. In this study, we performed a comprehensive biochemical and antiparasitic evaluation of Trypanosoma cruzi NMT (TcNMT), utilizing novel "in silico–identified inhibitors” to assess its potential as a therapeutic agent for Chagas disease.Methods: Recombinant TcNMT was cloned, expressed, and purified for enzymatic characterization. Catalytic activity and substrate affinity were evaluated using a fluorescence-based assay. Four in-silico-selected NMT inhibitors were screened for (i) enzyme inhibition, (ii) cytotoxicity in human cardiomyocytes, and (iii) antiparasitic activity in T. cruzi–infected cardiomyocytes. QUINE and the reference inhibitor DDD85646 were further characterized by calculating selectivity indices. Proteomic profiling of myristoylated proteins was conducted in amastigotes and trypomastigotes following treatment with DDD85646 to identify pathway-level effects.Results: All recombinant TcNMT preparations were catalytically active and displayed high affinity for peptide substrates. Among the screened compounds, QUINE showed moderate antiparasitic efficacy but very low cytotoxicity, yielding a high selectivity index (SI = 28.11). In contrast, DDD85646 exhibited greater antiparasitic potency but substantially higher host-cell toxicity (SI = 4.67). Proteomic analysis of DDD85646-treated parasites revealed downregulation of myristoylated proteins in both life stages, including ARF GTPases and enzymes associated with vesicular trafficking and lipid metabolism. Host cell proteomes remained largely unchanged.Discussion: Biochemical characterization and phenotypic testing support TcNMT as a viable therapeutic target for Chagas disease. QUINE demonstrates the most favorable pharmacological profile, combining antiparasitic activity with excellent selectivity and low host toxicity, making it a strong lead candidate for future drug optimization. Proteomics data indicate that NMT inhibition disrupts critical pathways required for parasite viability yet spares host cellular machinery, reinforcing the mechanistic selectivity of TcNMT targeting. Further studies are warranted to improve potency and evaluate in vivo efficacy.
publishDate 2026
dc.date.none.fl_str_mv 2026-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/195367
url http://sedici.unlp.edu.ar/handle/10915/195367
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/2296-889X
info:eu-repo/semantics/altIdentifier/doi/10.3389/fmolb.2025.1666768
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1868982610250694656
score 13.334379